Chemistry Reference
In-Depth Information
[259] Kier LB. Molecular orbital calculation of preferred conformations of acetylcholine,
muscarine, and muscarone. Mol. Pharmacol.1967, 3: 487-494.
[260] Barnum D, Greene J, Smellie A, Sprague P, Identification of common functional
configurations among molecules. J. Chem. Inf. Comput. Sci., 1996, 36: 563-571.
[261] Jones G, Willett P, Glen RC, A genetic algorithm for flexible molecular overlay and
pharmacophore elucidation. J. Comput. Aided Mol. Des., 1995, 9: 532-549.
[262] Richmond NJ, Abrams CA, Wolohan PR, Abrahamian E, Willett P, Clark RD,
GALAHAD: Pharmacophore identification by hypermolecular alignment of ligands in 3D.
J.Comput. Aided Mol. Des. 2006, 20: 567-587.
[263] Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA,PHASE: a new
engine for pharmacophore perception, 3D QSAR model development, and 3D database
screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des., 2006, 20:
647-671.
[264] Dixon SL, Smondyrev AM, Rao SN, PHASE: a novel approach to pharmacophore
modeling and 3D database searching. Chem. Biol. Drug Des., 2006, 67: 370-372.
[265] Bandyopadhyay D, Agrafiotis DK, A self-organizing algorithm for molecular alignment
and pharmacophore development. J. Comput. Chem., 2008, 29: 965-982.
[266] Feng J. Sanil A, Young SS. PharmID: pharmacophore identification using Gibbs sampling.
J. Chem. Inf. Model., 2006, 46: 1352-1359.
[267] Jones G. GAPE: an improved genetic algorithm for pharmacophore elucidation. J. Chem.
Inf. Model., 2010, 50: 2001-2018.
[268] Langer T, Pharmacophores in drug research. Mol. Inf., 2010, 29:470-475.
[269] Sanders MPA, McGuire R, Roumen L, de Esch IJP, de Vlieg J, Klompe JPG and de Graaf
C. From the protein's perspective: the benefits and challenges of protein structure-based
pharmacophore modeling. Med. Chem. Commun., 2012, 3: 28-38
[270] Sotriffer CA, Accounting for induced-fit effects in docking: What is possible and what is
not?, Current Topics in Medicinal Chemistry, 2011, 11:179-191.
[271] May A, Sieker, F, Zacharias, M. How to efficiently include receptor flexibility during
computational docking. Curr. Comput. Aided Drug Des., 2008, 4: 143-153.
[272] Wong CF, Flexible ligand-flexible protein docking in protein kinase systems. Biochim.
Biophys. Acta, 2008, 1784: 244-251.
[273] B-Rao, C, Subramanian, J, Sharma SD. Managing protein flexibility in docking and its
applications. Drug Discov. Today, 2009, 14: 394-400.
[274] Henzler AM, Rarey M, Protein flexibility in structure-basevirtual screening: from models
to algorithms. In: Virtual Screening Sotriffer C., Ed.; Wiley VCH: Weinheim, 2011.
[275] Jiang F, Kim, SH. "Soft docking": matching of molecular surface cubes. J. Mol. Biol.,
1991, 219: 79-102.
[276] Kokh DB, Wenzel W, Flexible side chain models improve enrichment rates in
in silico
screening. J. Med. Chem., 2008, 51:5919-5931.
[277] Gschwend DA, Good AC, Kuntz ID. Molecular docking towards drug discovery. J. Mol.
Recognit., 1996, 9: 175-186.
[278] Leach AR. Ligand docking to proteins with discrete side-chain flexibility. J. Mol. Biol.,
1994, 235: 345-356.
[279] Schaffer L. Verkhivker GM, Predicting structural effects iHIV-1 protease mutant
complexes with flexible ligand docking and protein side-chain optimization. Proteins:
Struct., Funct., Bioinform., 1998, 33: 295-310.
